title: [The concentrations of prolactin and estrogens in women with fibrocystic changes in the breast].
abstract: OBJECTIVE
  To evaluate the concentrations of prolactin and estrogens in blood sera in women with fibrocystic changes in the breast (FCC).
  
  
  METHODS
  The control group consisted of 32 women without any pathological changes in the breast (mean age 44.9 +/- 4.4 y.). The studied group comprised 81 women having FCC (mean age 45.5 +/- 3.5 y.). Both groups were divided into two subgroups according to age: the first subgroup ranged 40-44 y. and the second 45-51 y. The hormonal profiles, namely: prolactin in basal conditions (PRL I), and after metoclopramide-test (PRL II), follitropin (FSH), lutropin (LH), estradiol (E2), progesterone (P) were assayed by means of "bioMerioux" kits. Estrone (E1) was assayed by means of "DBC Diagnostic kits.
  
  
  RESULTS
  In both subgroups of the study group (40-44 and 45-51 y.) a significantly higher (p < 0.001) concentration of prolactin was shown after metoclopramide test, as well as significantly higher percentage increase in prolactin after metoclopramide test (p < 0.001) were shown in comparison with the control group. In age compartment of 40-44 y. in the study group significantly lower (p < 0.05), progesterone-estradiol index (PEL) was found in comparison with the control group. In age compartment of 45-51 y. a progesterone-estradiol index (PEL) in study group was significantly lower (p < 0.05) in comparison with the control group.
  
  
  CONCLUSIONS
  Functional hyperprolactinemia and relative hyperestrogenism are risk factors of the development concerning fibrocystic changes in the breast.
authors.affiliation: Samodzielnej Pracowni Menopauzy i Andropauzy Pomorskiej Akademii Medycznej w Szczecinie.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Sieja
authors.forename: Stanisław
authors.initials: S
authors.lastname: Stanosz
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000097:blood*; D004970:Estrone / Q000097:blood; D005260:Female; D005348:Fibrocystic Breast Disease / Q000097:blood* / Q000209:etiology; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000150:complications; D007986:Luteinizing Hormone / Q000097:blood; D008787:Metoclopramide; D008875:Middle Aged; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood*; D012307:Risk Factors
chemical_list: D004967:Estrogens; D004970:Estrone; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008787:Metoclopramide